Biosimilars offer high-quality, lower-cost cancer treatments. Learn how they’re helping patients and reshaping global healthcare budgets.

FDA biosimilar approvals reached a record 19 in 2024, with projections indicating that 2025 could surpass this milestone trend. This presents a golden opportunity for Contract Manufacturing ...

The Food and Drug Administration (FDA) has designated Otulfi ® (ustekinumab-aauz) as an interchangeable biosimilar to the reference product Stelara ® (ustekinumab).. Otulfi is a human ...

Here, we debunk seven myths about the Vikings. Related: Hårby Valkyrie: A 1,200-year-old gold Viking Age woman sporting a sword, shield and ponytail. The Vikings wore helmets with wings and horns.

For instance, Amgen’s Chairman and CEO, Robert Bradway, projected in 2022 that by 2030, Amgen’s biosimilars, including Amjeta and six others, could more than double the company's annual ...

Samsung Bioepis has released its Second Quarter 2025 Biosimilar Market Report, which provides the second quarter 2025 Average Sales Price and Wholesale Acquisition Cost of the commercially ...

Understanding biosimilars, biologics, and the challenges surrounding their regulation and pricing in the pharmaceutical industry. ... The Myth of Drug Regulation in India’ (2022).

The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and children with diabetes, the agency announced Friday.. Like its reference ...

Demand for biosimilars is predicted to be expanding at a compound annual growth rate of nearly 18% from $9.4 billion in 2023 to $66.9 billion in 2028 (1). This strong growth reflects both higher ...

Less than a decade since it secured its first FDA approval for a biosimilar, Amgen’s portfolio of the copycat drugs is growing and making strong contributions to the company’s top line.. In ...